uniQure (QURE) Cost of Revenue (2021 - 2026)
uniQure (QURE) posted Cost of Revenue of $350000.0 for Q2 2026, up 59.82% on a QoQ basis from $219000.0 in Q1 2026, and down 46.65% year-over-year from $656000.0 in Q2 2025.
Analysis
uniQure (QURE) Cost of Revenue (2021 - 2026) Analysis & Trends
uniQure has reported Cost of Revenue for 6 years, with the latest figure at $350000.0 in Q2 2026.
- On a quarterly basis, Cost of Revenue fell 46.65% year-over-year to $350000.0 in Q2 2026; TTM through Jun 2026 was $1.4 million, a 12.92% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 90.12% from the prior year.
- Cost of Revenue was $350000.0 for Q2 2026 at uniQure, up from $219000.0 in the prior quarter.
- The five-year high for Cost of Revenue was $9.1 million in Q1 2024, with the low at $197000.0 in Q1 2025.
- Average Cost of Revenue over 5 years is $2.2 million, with a median of $794500.0 recorded in 2022.
- The sharpest annual moves came in 2023 and 2025: Cost of Revenue jumped 2114.65% in 2023, then plunged 97.83% in 2025.
- Over 5 years, Cost of Revenue stood at $396000.0 in 2022, then surged by 2114.65% to $8.8 million in 2023, then tumbled by 91.37% to $757000.0 in 2024, then sank by 42.54% to $435000.0 in 2025, then decreased by 19.54% to $350000.0 in 2026.
- The last three Cost of Revenue figures came in at $350000.0 (Q2 2026), $219000.0 (Q1 2026), and $435000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 6.44 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 43.60 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 136.00 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 350,000.00 |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 2.81 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 149.39 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 21.06 Mn |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 350,000.00 |
| Mar 31, 2026 | 219,000.00 |
| Dec 31, 2025 | 435,000.00 |
| Sep 30, 2025 | 398,000.00 |
| Jun 30, 2025 | 656,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Sep 30, 2024 | 757,000.00 |
| Jun 30, 2024 | 7.23 Mn |
| Mar 31, 2024 | 9.08 Mn |
| Dec 31, 2023 | 8.77 Mn |
| Sep 30, 2023 | 1.01 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 2.44 Mn |
| Dec 31, 2022 | 396,000.00 |
| Sep 30, 2022 | 861,000.00 |
| Jun 30, 2022 | 832,000.00 |
| Dec 31, 2021 | 1.80 Mn |
| Jun 30, 2021 | 23.18 Mn |